DLL3 and large cell neuroendocrine carcinoma: Hermans et al. (17) found that expression of DLL3 was positive in 74% (70/94) of LCNEC and higher in 89% (8/9) of TP53 wild-type LCNEC than in 50% (29/58) of mutant-type (P = 0.035), indicating that DLL3 played a potential role in identifying molecular subtypes of LCNEC.